Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

955
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
955
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

582
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
582
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

2.8K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
2.8K
Management of Insomnia01:19

Management of Insomnia

807
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
807
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

2.2K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
2.2K
Narcolepsy01:07

Narcolepsy

848
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
848

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Really Care About Our Children's School Safety? The Proof Is in the Pudding.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

Thyroid hormone augmentation for bipolar disorder: a neurobiological and clinical narrative review.

International journal of bipolar disorders·2026
Same author

Electroconvulsive Therapy for the Neuropsychiatric Manifestations of Amyostatic-Akinetic Encephalitis Lethargica: A Case Report.

The journal of ECT·2026
Same author

Animal models that mirror bipolar disorder's pathophysiologic complexities: focused review of common models.

Expert opinion on drug discovery·2026
Same author

Mood Stabilizers Are the First Line of Treatment for Bipolar Disorder.

Southern medical journal·2026
Same author

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Serum Levels of IFN-γ and NGF as Potential Biomarkers of Depressive Disorders.

Acta neuropsychiatrica·2026
Same journal

The Danish Region Midt Schizophrenia Cohort - Representative, long-term follow-up of first-episode schizophrenia spectrum disorder.

Acta neuropsychiatrica·2026
Same journal

The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.

Acta neuropsychiatrica·2026
Same journal

Breaking down the ADHD construct to build a valid diagnosis.

Acta neuropsychiatrica·2026
Same journal

A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer's disease and dementia.

Acta neuropsychiatrica·2026
Same journal

Age-dependent increase in peripheral neuropeptide Y with no cross-sectional link to depression.

Acta neuropsychiatrica·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.4K

Suvorexant: something new for sleep?

Abhishek Reddy1, Sowmya C Puvvada1, Satyanarayana Kommisetti1

  • 1Department of Psychiatry,University of Louisville School of Medicine,Louisville,KY,USA.

Acta Neuropsychiatrica
|November 15, 2014
PubMed
Summary
This summary is machine-generated.

Suvorexant, an orexin receptor antagonist, effectively treats insomnia by reducing wakefulness. It offers a favorable side effect profile with less drowsiness and cognitive issues compared to other sleep aids.

Keywords:
suvorexant

More Related Videos

The Sleep Nullifying Apparatus: A Highly Efficient Method of Sleep Depriving Drosophila
06:06

The Sleep Nullifying Apparatus: A Highly Efficient Method of Sleep Depriving Drosophila

Published on: December 14, 2020

4.4K
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.4K
The Sleep Nullifying Apparatus: A Highly Efficient Method of Sleep Depriving Drosophila
06:06

The Sleep Nullifying Apparatus: A Highly Efficient Method of Sleep Depriving Drosophila

Published on: December 14, 2020

4.4K
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.9K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Orexin (hypocretin) is a neuropeptide crucial for promoting central nervous system arousal.
  • Insomnia is a prevalent sleep disorder affecting millions worldwide.
  • Current insomnia pharmacotherapies may present significant side effects.

Purpose of the Study:

  • To evaluate suvorexant as a novel pharmacotherapy for insomnia.
  • To assess the efficacy and safety profile of suvorexant in managing insomnia.
  • To compare suvorexant's benefits against existing sleep aids.

Main Methods:

  • Review of clinical data on suvorexant's mechanism of action.
  • Analysis of studies comparing suvorexant to placebo and other insomnia medications.
  • Assessment of reported side effects, including drowsiness and cognitive impairment.

Main Results:

  • Suvorexant antagonizes orexin receptors, thereby decreasing wakefulness.
  • Clinical use shows potential for diminished drowsiness and less cognitive dysfunction.
  • Preliminary data suggest a lack of rebound insomnia or drug dependence.

Conclusions:

  • Suvorexant represents a promising therapeutic option for insomnia.
  • Its favorable side effect profile may enhance patient adherence and outcomes.
  • Further research may solidify suvorexant's role in insomnia pharmacotherapy.